Abstract:Introduction: To identify the absolute risk of specific HPV genotype for cervical intraepithelial neoplasia grade 2/3 or worse (CIN2/3+) and form the risk-based management strategy by extended HPV genotyping in HPV positive population.Methods: HPV genotyping was performed based on 3-years cervical cancer screening cohort including 10314 women from 2 clinical trials. The study endpoints were histological CIN2+/3+. The prevalence of specific HPV genotype was calculated by minimum estimate, any type estimate and hierarchical attribution estimate. The absolute CIN2+/3+ risks of specific HPV genotype, cytology and combined test were estimated and risk-based management strategy was established according to ASCCP guideline. The performance of conventional and risk-based management strategies for non-16/18 HPVs to detect CIN2+/3+ were further evaluated.Findings: Eligible data were available for 8370 women with median age of 48 (IQR 42-53). At baseline, HPV positive women were 1062, including 424 multiple infections and 639 single infections. CIN2+/3+ cases were 113/74, 23/8, 20/7 and 52/31 at baseline, the 1st, 2nd and 3rd year of visit. Women with multiple HPV infections at baseline were prone to persistent infection than single infection (p<0.0001). HPV16 and 52 were top two ranking among baseline and 3-years cumulative CIN2+/3+ cases. Based on the absolute risk of specific HPV genotype combined with cytology for CIN2+/3+, all non-16/18 HPVs were divided into 4 risk stratified groups. Compared to conventional strategy, the risk-based strategies had higher specificity (p=0.0000) and PPV (p=0.0322) to detect CIN3+, and needed fewer colposcopies for each CIN3+ case.Interpretation: We proposed a new extended HPV genotyping protocol based on the absolute risk of specific HPV genotype, and corresponding management thresholds were suggested for achieving the precise risk-based management of HPV positive population.Funding Information: Supported by the key research and development program of Zhejiang province, China (Grant No: 2020C03025).Declaration of Interests: All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.Ethics Approval Statement: The study was approved by the Ethics Committee of Women’s Hospital, Zhejiang University School of Medicine (IRB-20200240-R). Informed consent was obtained for clinical trial.

Human Papillomavirus Genotyping to Predict the Risk of Cervical Precancerous Lesions or Cancer in Women with Minor Abnormal Cytology in China.

Clinical Significance of Genotyping for Human Papillomavirus (HPV) 16 18/45 Combined with Cytology in Cervical Exfoliated Cells in HPV Oncogenic Mrna-Positive Women

Performance of Human Papillomavirus (HPV) 16 and 18/45 Genotyping Combined with Age Stratification in the Triaging of Women with Histologic Low-Grade Squamous Intraepithelial Lesions Preceded by HPV Oncogenic Mrna-Positive/normal or Mildly Abnormal Cytology: A Longitudinal Study

The role of human papillomavirus genotyping for detecting high-grade intraepithelial neoplasia or cancer in HPV-positive women with normal cytology: a study from a hospital in northeastern China

Extended Human Papilloma Virus Genotyping for Risk Assessment of Cervical Intraepithelial Neoplasia Grade 2 or Worse in a Cohort Study

Efficient combination of Human Papillomavirus Genotyping for the triage of women with Atypical Squamous Cells of Undetermined Significance in Chinese rural population: A population-based study

Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology

The role of high-risk HPV genotyping in the detection of high-grade intraepithelial neoplasia or cancer in women with negative cytology but positivity for HPV: A hospital-based investigation in northeastern China

Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology.

The significance of human papillomavirus receptors related genes variants in cervical cancer screening: a longitudinal study of Chinese population

Diagnostic accuracy of extended HPV DNA genotyping and its application for risk-based cervical cancer screening strategy

The Study of Human Papillomavirus Genotyping in Cervical Cancer

Clinical efficacy of human papillomavirus (HPV) genotyping in screening for cervical disorders

Risk stratification for cervical neoplasia using extended high-risk HPV genotyping in women with ASC-US cytology: A large retrospective study from China

Prevalence of High-Risk Human Papillomavirus and Cervical Lesion Risk Factors: A Population-Based Study in Zhejiang, China 2010-2019

Performance of High-Risk Human Papillomavirus Testing in the Triage of Abnormal Cervical Cytology among Chinese Younger Women in Shanghai, China

[Use of High-Risk Human Papillomavirus DNA Testing to Deal with Atypical Squamous Cells Undetermined Significance and Low Squamous Intraepithelial Lesion].

[Risk stratification of type-specific human papillomavirus for cervical precancers: evidence from a cross-sectional study in Shenzhen]

The Triage Effectiveness of an Extended High-Risk Human Papillomavirus Genotyping Assay for Women with Cytology Showing Atypical Squamous Cells of Undetermined Significance in China

The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases

Human papillomavirus genotyping for predicting disease progression in women with biopsy-negative or cervical intraepithelial neoplasia grade 1 of low-grade intraepithelial lesion cytology